Agenus Inc. (NASDAQ:AGEN) has received an average recommendation of “Hold” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $5.81.

Several research firms have recently issued reports on AGEN. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Wednesday, October 25th. ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th.

Shares of Agenus (AGEN) opened at $3.69 on Thursday. Agenus has a 12-month low of $3.20 and a 12-month high of $5.45. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55.

Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) EPS for the quarter, meeting analysts’ consensus estimates of ($0.37). The firm had revenue of $3.40 million during the quarter, compared to the consensus estimate of $5.91 million. The firm’s revenue for the quarter was down 24.4% on a year-over-year basis. analysts anticipate that Agenus will post -1.19 EPS for the current fiscal year.

In related news, CEO Garo H. Armen bought 100,000 shares of the company’s stock in a transaction on Monday, October 30th. The shares were purchased at an average price of $3.55 per share, for a total transaction of $355,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.90% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY grew its stake in shares of Agenus by 12.2% during the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock valued at $211,000 after buying an additional 6,101 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Agenus by 15.1% during the second quarter. Alliancebernstein L.P. now owns 144,700 shares of the biotechnology company’s stock valued at $566,000 after buying an additional 19,000 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Agenus by 11.4% during the second quarter. Wells Fargo & Company MN now owns 520,142 shares of the biotechnology company’s stock valued at $2,033,000 after buying an additional 53,343 shares during the last quarter. Northern Trust Corp grew its stake in shares of Agenus by 4.1% during the second quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after buying an additional 37,239 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Agenus by 6.8% during the first quarter. Vanguard Group Inc. now owns 3,356,423 shares of the biotechnology company’s stock worth $12,653,000 after purchasing an additional 215,151 shares during the period. 37.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Agenus Inc. (AGEN) Receives Consensus Rating of “Hold” from Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/07/agenus-inc-agen-receives-consensus-rating-of-hold-from-brokerages.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.